Form 4: C4 Therapeutics Chief Accounting Officer Reports Tax-Related Share Withholding
SEC Form 4 Filing
Mark Mossler, Chief Accounting Officer of C4 Therapeutics, reports the withholding of shares to cover tax obligations related to vested restricted stock units.
Summary
- On February 14, 2025, Mark Mossler, the Chief Accounting Officer of C4 Therapeutics, Inc. (CCCC), had 1,586 common stock shares withheld by the issuer to satisfy tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs).
- Following this transaction, Mossler directly owns 18,204 shares of C4 Therapeutics common stock.
Sentiment
Score: 5
Explanation: The filing reflects a routine transaction related to tax obligations, indicating a neutral sentiment.
Industry Context
This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a standard procedure for tax obligations.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of transaction: Shares withheld for tax obligations. |
| 02/18/2025 | Date of signature on the Form 4 filing. |
Keywords
C4 Therapeutics, CCCC, Form 4, SEC Filing, Insider Transaction, Mark Mossler, Chief Accounting Officer, Restricted Stock Units, Tax Withholding, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.